Why a cure can be hard to sell
A medicine for a chronic condition can generate sales for years: patients keep taking it, and insurers or public health systems keep paying for refills. A treatment that works once and ends the illness has a different commercial shape. The benefit may last, but the purchase does not repeat.
That mismatch was the business question behind a 2018 Goldman Sachs biotech report. It was not simply asking whether a cure could help patients. It was asking whether a company could earn enough from a one-time treatment to justify developing it.
The price has to carry more weight
Drug development is costly and uncertain. A company may spend years testing a treatment without knowing whether it will work or win approval. With a one-time cure, the eventual price may need to reflect not only the dose, but also the research investment and the value of avoiding years of illness and ongoing care.
That creates a tension. A high upfront price can make a treatment difficult for insurers and health systems to afford, even if it could reduce costs over time. And because fewer patients may need it in later years, a company cannot count on a stable stream of repeat purchases to recover its investment.
Better outcomes, different incentives
The economics depend on the disease and the treatment. A cure for a large group of patients may support a different business than one for a rare condition; a treatment that lasts for years but does not permanently cure may also bring in future sales. Payment arrangements can spread a large bill over time or tie payment to whether the treatment works, though those approaches bring their own complications.
The underlying tradeoff is stark: the more completely a medicine solves the patient’s problem, the less reason that patient has to buy it again. A sustainable cure business must make that one successful treatment count—for patients, payers, and the company that took the risk of developing it.
